Palla Pharma (ASX:PAL) Retained Earnings : A$-211.04 Mil (As of Jun. 2021)

View and export this data going back to 2015. Start your Free Trial

What is Palla Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Palla Pharma's retained earnings for the quarter that ended in Jun. 2021 was A$-211.04 Mil.

Palla Pharma's quarterly retained earnings declined from Jun. 2020 (A$-152.20 Mil) to Dec. 2020 (A$-177.94 Mil) and declined from Dec. 2020 (A$-177.94 Mil) to Jun. 2021 (A$-211.04 Mil).

Palla Pharma's annual retained earnings declined from Dec. 2018 (A$-135.54 Mil) to Dec. 2019 (A$-143.18 Mil) and declined from Dec. 2019 (A$-143.18 Mil) to Dec. 2020 (A$-177.94 Mil).

Palla Pharma Retained Earnings Historical Data

The historical data trend for Palla Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palla Pharma Retained Earnings Chart

Palla Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Retained Earnings

Get a 7-Day Free Trial

-113.39

-130.09

-135.54

-143.18

-177.94

Palla Pharma Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21
Retained Earnings	Get a 7-Day Free Trial							-139.63	-143.18	-152.20	-177.94	-211.04

Palla Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Palla Pharma (ASX:PAL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Palla Pharma (ASX:PAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Palla Pharma Ltd (ASX:PAL) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/- Mertons Corporate Services, 330 Collins Street, Level 7, Melbourne, VIC, AUS, 3000

Website

http://www.tpienterprises.com

Palla Pharma Ltd is a licensed poppy processor in Australia. It is engaged in producing narcotic raw material for the international pharmaceutical industry. It also supplies narcotic raw material and culinary poppy seed.

Palla Pharma (ASX:PAL) Headlines

From GuruFocus

Proficient Auto Logistics Announces Pricing of Initial Public Offering

By Business Wire • 05-09-2024